VDAC2 and nasopharyngeal carcinoma: In NPC patients, TRIM21 promotes the degradation of VDAC2 via K48-linked ubiquitination, which inhibits pore formation by VDAC2 oligomers for mitochondrial DNA (mtDNA) release, thereby inhibiting type I IFN responses following radiation exposure (127).